Shorter Exclusivity In House OTC Monograph Bill Could Gain Industry Acceptance To Speed Passage

The length of exclusivity periods is the only major difference between pending US House and Senate bills, both largely based on a proposal developed by FDA and drug industry representatives. Committees in both chambers are expected to vote on moving the bipartisan proposals to floor votes within two months.